Sep. 4 at 4:46 PM
$PLRX is one of the more interesting biotech valuation setups I’ve found at this price.
Pliant had roughly
$160M in cash and investments at June 30 while the market cap is around
$70M. Even accounting for ongoing burn, the company says runway extends into H2 2028.
PLN-101095 is still early, but the signal is worth watching. Three confirmed responders showed very deep tumor reductions, averaging around 89%, with durable responses. FDA has also granted Fast Track designation.
The risk is obvious: the efficacy dataset is still very small. A few strong responders can disappear once the expansion cohorts get larger.
That’s the thesis. PLRX doesn’t need perfection at this valuation. It needs the FORTIFY expansion cohorts to show that the early responses were reproducible rather than noise.
